Please provide your email address to receive an email when new articles are posted on . The daratumumab-based regimen conferred significantly longer PFS than standard of care. Three-quarters of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

HORSHAM, Pa., July 12, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO ® ...

Data from the Apollo study provide proof for the subcutaneous administration (sc) of daratumumab (Darzalex Faspro) in combination with pomalidomide (Pomalyst) and dexamethasone (Pd) for patients with ...

Daratumumab produced rapid and sustained platelet responses in adults with immune thrombocytopenia (ITP), according to a recent single-center, open-label, phase 2 clinical trial (NCT05562882). Despite ...

Although it may take time for physicians to become used to this regimen, there is greater urgency now that it can be given ...

The monoclonal antibody daratumumab (Darzalex) has been granted Breakthrough designation, the second for this drug, for use in combination with either lenalidomide (Revlimid) and dexamethasone or ...

Please provide your email address to receive an email when new articles are posted on . Daratumumab delayed progression of smoldering multiple myeloma compared with active monitoring. Among those who ...

The evaluation committee considered evidence submitted by Janssen, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for ...

BEERSE, BELGIUM, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) approved the indication extension for ...